Page last updated: 2024-08-21

cyclopentane and Bone Loss, Osteoclastic

cyclopentane has been researched along with Bone Loss, Osteoclastic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Hirai, K; Ibaragi, S; Ishii, S; Kobayashi, H; Mandai, H; Nakagawa, S; Nakayama, M; Omori, K; Sakaida, K; Sako, H; Suga, S; Takashiba, S; Yamamoto, S; Yamamoto, T; Yamashiro, K; Yoshimura, H	1

Other Studies

1 other study(ies) available for cyclopentane and Bone Loss, Osteoclastic

Article	Year
The fungal metabolite (+)-terrein abrogates osteoclast differentiation via suppression of the RANKL signaling pathway through NFATc1. International immunopharmacology, 2020, Volume: 83 Topics: Acid Phosphatase; Animals; Aspergillus; Bone Marrow Cells; Bone Resorption; Cathepsin K; Cell Differentiation; Cyclopentanes; Dose-Response Relationship, Drug; Isoenzymes; Macrophages; Male; Mice; Mice, Inbred C57BL; NFATC Transcription Factors; Osteoclasts; Osteogenesis; RANK Ligand; Signal Transduction	2020

Article

Year

The fungal metabolite (+)-terrein abrogates osteoclast differentiation via suppression of the RANKL signaling pathway through NFATc1.

International immunopharmacology, 2020, Volume: 83

Topics: Acid Phosphatase; Animals; Aspergillus; Bone Marrow Cells; Bone Resorption; Cathepsin K; Cell Differentiation; Cyclopentanes; Dose-Response Relationship, Drug; Isoenzymes; Macrophages; Male; Mice; Mice, Inbred C57BL; NFATC Transcription Factors; Osteoclasts; Osteogenesis; RANK Ligand; Signal Transduction

2020